- Ludwig Enterprises Inc. (LUDG, Financial) appoints Charles T. Todd, Jr. as CEO and Chairman to lead transformation.
- Todd has extensive experience, having scaled BioReference Laboratories to a multi-billion dollar sale.
- Company focuses on developing non-invasive cancer screening technology using AI.
Ludwig Enterprises Inc. (LUDG) has announced the appointment of Charles T. Todd, Jr. as the new Chief Executive Officer and Chairman of the Board. This strategic leadership change is aimed at steering the company as it transitions from a research-focused enterprise to a comprehensive healthcare solutions provider.
Mr. Todd brings over 40 years of experience in the Clinical Laboratory Industry. He is renowned for founding the first cancer specialty laboratory in the United States and for his pivotal role at BioReference Laboratories. Under his leadership as Executive Vice President, BioReference Laboratories grew to become the third-largest clinical laboratory in the country, culminating in its acquisition by OPKO Health for $1.2 billion in 2015.
Ludwig Enterprises is currently developing a cutting-edge, patent-pending cancer screening technology. This innovation utilizes 48 mRNA markers, nanoscale detection, and artificial intelligence (AI) to deliver a non-invasive, early detection tool via a cheek swab, with a particular emphasis on breast cancer screening. The company envisions that this innovative approach will grant them a competitive edge in the healthcare market.
Speaking on his new role, Mr. Todd expressed his enthusiasm about leading the company's transformative journey and leveraging his experience to commercialize their cancer diagnostic programs. The company is also in the process of rebranding and plans to operate under the name Revealia Diagnostics, Inc.
Marvin S. Hausman, MD, Co-Founder and Chief Science Officer of Ludwig Enterprises, highlighted Todd's strategic vision and expertise, underlining the positive impact anticipated for both shareholders and the wider patient community as the company rolls out its cancer diagnostic program.
For further information, please visit the company's website at ludwigent.com.
